Intra-Cellular Therapies, Inc.
ITCI
Hisse Senetlerindeki Sıralama
#1690
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Hisse Fiyatı
$131.87
Son senkronizasyon: 2025-04-02
Piyasa Değeri
$12.68B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Intra-Cellular Therapies, Inc. (ITCI)
Kategori
Healthcare
Intra-Cellular Therapies, Inc. (ITCI) için P/S oranı
October 2026 itibarıyla P/S oranı TTM: 20.63
Intra-Cellular Therapies, Inc. şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 20.63'dir. 2023 yılının sonunda şirketin P/S oranı 14.79 idi.
Intra-Cellular Therapies, Inc. için P/S oranı geçmişi 2013 - 2026 arası
Her yılın sonunda P/S oranı
| Yıl | P/S Oranı | Değiştir |
|---|---|---|
| 2026 (TTM) | 20.63 | 63.10% |
| 2024 | 12.65 | -14.45% |
| 2023 | 14.79 | -25.98% |
| 2022 | 19.98 | -61.62% |
| 2021 | 52.05 | -47.59% |
| 2020 | 99.31 | -99.68% |
| 2019 | 31.24K | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | 2.72K | 37.86% |
| 2016 | 1.97K | -90.69% |
| 2015 | 21.20K | 2,320.46% |
| 2014 | 875.93 | 827.98% |
| 2013 | 94.39 | 0.00% |
Benzer şirketler veya rakipler için P/S oranı
| Şirket | P/S Oranı | P/S Oranı Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -65.79% |
IN
|
